SUMMARY  

• A literature search did not identify any information related to safety concerns of using SPRAVATO for patients with treatment-resistant depression or major depressive disorder and active suicidal ideation with intent who are also diagnosed with active coronavirus disease 2019 (COVID-19).
• For patients currently receiving SPRAVATO treatment who have been diagnosed with active COVID-19, clinicians should use clinical judgment to decide whether to delay treatment until the patient is recovered or to continue treatment with SPRAVATO as scheduled. It will be important to evaluate the risk benefit of continued treatment based on the patient’s clinical status in terms of depressive symptoms versus the severity of symptoms from COVID-19.
• If a decision is made to continue treatment, appropriate precautions should be taken to minimize potential for spread of infection and to protect clinical and office staff. Please see the latest information on the CDC website for the latest infection prevention and control recommendations for patients with suspected or confirmed COVID-19 in healthcare settings.¹

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 12 November 2024.